.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
McKesson
Cantor Fitzgerald
QuintilesIMS
Moodys
Covington
Medtronic
Colorcon
Daiichi Sankyo
Argus Health

Generated: December 13, 2017

DrugPatentWatch Database Preview

LEVAQUIN Drug Profile

« Back to Dashboard

Which patents cover Levaquin, and what generic alternatives are available?

Levaquin is a drug marketed by Janssen Pharms and is included in three NDAs. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in LEVAQUIN is levofloxacin. There are twenty-nine drug master file entries for this compound. Sixty-four suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Janssen PharmsLEVAQUINlevofloxacinINJECTABLE;INJECTION020635-001Dec 20, 1996APRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsLEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINERlevofloxacinINJECTABLE;INJECTION020635-002Dec 20, 1996DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsLEVAQUINlevofloxacinTABLET;ORAL020634-001Dec 20, 1996ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsLEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINERlevofloxacinINJECTABLE;INJECTION020635-003Dec 20, 1996DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsLEVAQUINlevofloxacinINJECTABLE;INJECTION020635-004Dec 20, 1996APRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsLEVAQUINlevofloxacinSOLUTION;ORAL021721-001Oct 21, 2004DISCNYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Janssen PharmsLEVAQUINlevofloxacinTABLET;ORAL020634-003Sep 8, 2000ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsLEVAQUINlevofloxacinTABLET;ORAL020634-002Dec 20, 1996ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Janssen PharmsLEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINERlevofloxacinINJECTABLE;INJECTION020635-005Dec 20, 1996DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LEVAQUIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen PharmsLEVAQUINlevofloxacinTABLET;ORAL020634-002Dec 20, 1996► Subscribe► Subscribe
Janssen PharmsLEVAQUINlevofloxacinINJECTABLE;INJECTION020635-001Dec 20, 1996► Subscribe► Subscribe
Janssen PharmsLEVAQUINlevofloxacinTABLET;ORAL020634-002Dec 20, 1996► Subscribe► Subscribe
Janssen PharmsLEVAQUINlevofloxacinTABLET;ORAL020634-003Sep 8, 2000► Subscribe► Subscribe
Janssen PharmsLEVAQUINlevofloxacinTABLET;ORAL020634-001Dec 20, 1996► Subscribe► Subscribe
Janssen PharmsLEVAQUINlevofloxacinSOLUTION;ORAL021721-001Oct 21, 2004► Subscribe► Subscribe
Janssen PharmsLEVAQUINlevofloxacinTABLET;ORAL020634-001Dec 20, 1996► Subscribe► Subscribe
Janssen PharmsLEVAQUINlevofloxacinINJECTABLE;INJECTION020635-004Dec 20, 1996► Subscribe► Subscribe
Janssen PharmsLEVAQUINlevofloxacinINJECTABLE;INJECTION020635-001Dec 20, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for LEVAQUIN

Drugname Dosage Strength RLD Submissiondate
levofloxacinOral Solution25 mg/mLLevaquin7/30/2009

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Express Scripts
Citi
Accenture
Federal Trade Commission
Merck
Julphar
Medtronic
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot